FREE Account Opening + No Clearing Fees
Loading...

Glenmark Life Sciences IPO vs Nuvoco IPO

Comparision between Glenmark Life Sciences IPO and Nuvoco IPO.

IPO Details

Glenmark Life Sciences IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Nuvoco IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Glenmark Life Sciences IPO is up to ₹1,513.60 Cr whereas the issue size of the Nuvoco IPO is up to ₹5,000.00 Cr. The final issue price of Glenmark Life Sciences IPO is ₹720.00 per share and of Nuvoco IPO is ₹570.00 per share.

  Glenmark Life Sciences IPO Nuvoco IPO
Face Value ₹2 per share ₹10 per share
Issue Price (Lower) ₹695.00 per share ₹560.00 per share
Issue Price (Upper) ₹720.00 per share ₹570.00 per share
Issue Price (Final) ₹720.00 per share ₹570.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 20 shares 26 shares
Fresh Issue Size
Fresh Issue Size (Amount) up to ₹1,060.00 Cr up to ₹1,500.00 Cr
OFS Issue Size 63,00,000 shares
OFS Issue Size (Amount) up to ₹453.60 Cr up to ₹3,500.00 Cr
Issue Size Total
Issue Size Total (Amount) up to ₹1,513.60 Cr up to ₹5,000.00 Cr

IPO Timetable

Glenmark Life Sciences IPO opens on Jul 27, 2021, while Nuvoco IPO opens on Aug 09, 2021. The closing date of Glenmark Life Sciences IPO and Nuvoco IPO is Jul 29, 2021, and Aug 11, 2021, respectively.

  Glenmark Life Sciences IPO Nuvoco IPO
Anchor Bid Date
Issue Open Jul 27, 2021 Aug 09, 2021
Issue Close Jul 29, 2021 Aug 11, 2021
Basis Of Allotment (Tentative) Aug 03, 2021 Aug 17, 2021
Initiation of Refunds (Tentative) Aug 04, 2021 Aug 18, 2021
Credit of Share (Tentative) Aug 05, 2021 Aug 20, 2021
Listing date (Tentative) Aug 06, 2021 Aug 23, 2021
Anchor Lockin End date 1 Sep 02, 2021 Sep 16, 2021
Anchor Lockin End date 2 Nov 01, 2021 Nov 15, 2021

Financials

Glenmark Life Sciences IPO P/E ratio is , as compared to Nuvoco IPO P/E ratio of .

  Glenmark Life Sciences IPO Nuvoco IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 19,970.75 17,256.04 14,753.95
Total Revenue 18,859.76 15,493.03 8,868.65
Profit After Tax 3,515.81 3,130.98 1,955.92
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 1,99,075.70 134,443.22 132,617.03
Total Revenue 75,226.93 68,299.44 71,058.88
Profit After Tax (259.19) 2,492.55 (264.88)
Promoter Shareholding (Pre-Issue) 100% 95.24%
Promoter Shareholding (Post-Issue) 82.84% 71.03%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Glenmark Life Sciences IPO retail investors (RII) are offered 75,43,130 shares while in Nuvoco IPO retail investors are offered 75,43,130 shares. Qualified institutional buyers (QIB) are offered 42,42,379 shares in Glenmark Life Sciences IPO and 1,78,57,143 shares in Nuvoco IPO.

  Glenmark Life Sciences IPO Nuvoco IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 42,42,379 shares 1,78,57,143 shares
NII 32,32,770 shares 1,33,92,858 shares
RII 75,43,130 shares 3,12,50,000 shares
Employee 0 shares 0 shares
Others
Total 1,50,18,279 shares 6,25,00,001 shares

Bids Received (Subscription)

Glenmark Life Sciences IPO subscribed 44.17x in total, whereas Nuvoco IPO subscribed 1.71x.

  Glenmark Life Sciences IPO Nuvoco IPO
QIB (times) 36.97x 4.23x
NII (times) 122.54x 0.66x
Big NII (times)
Small NII (times)
RII (times) 14.63x 0.73x
Employee (times)
Other (times)
Total (times) 44.17x 1.71x

Comments

Add a public comment...